High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study

Table 5 Longitudinal data analysis of survival outcomes by KRAS, TP53, and CDKN2A mutations

Gene	Measured time	OS ≥ 6 months	OS ≥ 12 months	PFS ≥ 6 months	PFS ≥ 12 months	PR as BOR^a	PD as BOR^a
Gene	Measured time	P value	P value	P value	P value	P value	P value
KRAS	2	0.001	0.026	0.021	0.178	0.344	0.012
	3	0.014	0.002	0.002	0.057	0.315	0.681
TP53	2	< 0.001	0.083	0.059	0.151	0.108	0.015
	3	0.001	0.149	0.098	0.184	0.044	0.164
CDKN2A	2	0.027	0.027	0.004	0.465	0.202	NE
	3	0.031	0.031	0.002	0.439	0.176	NE

Bold values indicate statistical significance (P < 0.05)
OS overall survival, PFS progression-free survival, PR partial response, PD progressive disease, BOR best objective response, NE not estimable
^aDuring first-line chemotherapy

ISSN: 1479-5876